Semaglutide GLP-1 is also not recommended for individuals with a history of severe gastrointestinal disease or gastroparesis, as it may exacerbate these conditions
All information on this website is for educational purposes only
However, the semaglutide group received a relatively low dose, highlighting the need for further study
Retatrutide, known scientifically as LY3437943, is a triple agonist, working on three crucial hormone receptors that play significant roles in weight management: GLP-1, GIP, and GCG
Effects of incretin-based therapy on CV complications In line with previous evidence accrued in patients with T2D 83 , recent data demonstrated for the first time that incretin-based therapy was associated with CV risk reduction in patients with overweight or obesity with normoglycemia or prediabetes
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases